Clinical Trial Update: The Efficacy of Alirocumab for Thin-cap fIbroatheroma in Patients With Coronary Artery Disease Estimated by Optical Coherence Tomography [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating the efficacy of alirocumab for thin-cap fibroatheroma in patients with coronary artery disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• alirocumab (alirocumab)

Snippet

Sponsor: Kobe University | Conditions: Coronary Artery Disease, Thin-cap fIbroatheroma | Phase 4 | Status: UNKNOWN